Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Attention Deficit Disorder with Hyperactivity | 66 | 2024 | 3707 | 7.390 |
Why?
|
Central Nervous System Stimulants | 31 | 2024 | 1176 | 6.240 |
Why?
|
Methylphenidate | 19 | 2024 | 488 | 3.960 |
Why?
|
Social Control, Informal | 3 | 2013 | 44 | 1.200 |
Why?
|
Executive Function | 6 | 2024 | 1388 | 1.080 |
Why?
|
Adrenergic Uptake Inhibitors | 4 | 2014 | 186 | 0.910 |
Why?
|
Delayed-Action Preparations | 12 | 2021 | 961 | 0.910 |
Why?
|
Viloxazine | 1 | 2024 | 14 | 0.890 |
Why?
|
Propylamines | 3 | 2014 | 161 | 0.850 |
Why?
|
Amphetamine | 2 | 2023 | 224 | 0.800 |
Why?
|
Salts | 1 | 2019 | 62 | 0.660 |
Why?
|
Dextroamphetamine | 4 | 2012 | 134 | 0.650 |
Why?
|
Butyrates | 1 | 2020 | 169 | 0.650 |
Why?
|
United States Food and Drug Administration | 2 | 2024 | 1662 | 0.630 |
Why?
|
Tetrahydrofolates | 1 | 2019 | 58 | 0.620 |
Why?
|
Automobile Driving | 5 | 2017 | 445 | 0.620 |
Why?
|
Emotions | 3 | 2013 | 2742 | 0.530 |
Why?
|
Memantine | 2 | 2016 | 108 | 0.500 |
Why?
|
Sleep | 5 | 2022 | 4759 | 0.480 |
Why?
|
Psychiatric Status Rating Scales | 14 | 2019 | 6011 | 0.480 |
Why?
|
Penile Erection | 1 | 2014 | 101 | 0.450 |
Why?
|
Reaction Time | 2 | 2019 | 2087 | 0.440 |
Why?
|
Psychomotor Performance | 3 | 2017 | 1880 | 0.430 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 9 | 2019 | 1990 | 0.430 |
Why?
|
Pilot Projects | 10 | 2023 | 8642 | 0.420 |
Why?
|
Ambulatory Care | 1 | 2024 | 2770 | 0.420 |
Why?
|
Double-Blind Method | 16 | 2023 | 12341 | 0.410 |
Why?
|
Adolescent Psychiatry | 2 | 2024 | 156 | 0.400 |
Why?
|
Adaptation, Psychological | 4 | 2019 | 2632 | 0.390 |
Why?
|
Amphetamines | 2 | 2011 | 143 | 0.380 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2023 | 10756 | 0.370 |
Why?
|
Child Psychiatry | 2 | 2024 | 227 | 0.370 |
Why?
|
Adult | 52 | 2024 | 221120 | 0.370 |
Why?
|
Quinolones | 1 | 2014 | 378 | 0.360 |
Why?
|
Medicaid | 1 | 2024 | 2813 | 0.350 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2012 | 446 | 0.330 |
Why?
|
Visual Perception | 1 | 2017 | 1386 | 0.320 |
Why?
|
Occupations | 1 | 2010 | 517 | 0.300 |
Why?
|
Siblings | 2 | 2012 | 824 | 0.290 |
Why?
|
Polysomnography | 2 | 2022 | 1848 | 0.280 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 2012 | 894 | 0.270 |
Why?
|
Telemedicine | 1 | 2024 | 3051 | 0.270 |
Why?
|
Neuropsychological Tests | 6 | 2019 | 7046 | 0.260 |
Why?
|
Treatment Outcome | 21 | 2024 | 64681 | 0.260 |
Why?
|
Humans | 67 | 2024 | 761222 | 0.260 |
Why?
|
Adolescent | 25 | 2024 | 88300 | 0.240 |
Why?
|
Bulimia Nervosa | 1 | 2006 | 205 | 0.230 |
Why?
|
Sleep Initiation and Maintenance Disorders | 2 | 2021 | 1081 | 0.220 |
Why?
|
Piperazines | 1 | 2014 | 2522 | 0.220 |
Why?
|
Czech Republic | 1 | 2023 | 74 | 0.220 |
Why?
|
Young Adult | 16 | 2024 | 59222 | 0.190 |
Why?
|
Social Class | 1 | 2010 | 1993 | 0.190 |
Why?
|
Health Benefit Plans, Employee | 1 | 2024 | 332 | 0.190 |
Why?
|
Aging | 2 | 2018 | 8702 | 0.190 |
Why?
|
Antipsychotic Agents | 1 | 2014 | 3064 | 0.180 |
Why?
|
Male | 43 | 2024 | 360703 | 0.180 |
Why?
|
Child | 15 | 2024 | 80154 | 0.170 |
Why?
|
Comorbidity | 9 | 2024 | 10516 | 0.170 |
Why?
|
Insurance Claim Review | 1 | 2024 | 741 | 0.160 |
Why?
|
Female | 43 | 2024 | 392552 | 0.160 |
Why?
|
Folate Receptor 1 | 1 | 2019 | 40 | 0.160 |
Why?
|
GTP Cyclohydrolase | 1 | 2019 | 47 | 0.160 |
Why?
|
Patient Selection | 1 | 2010 | 4246 | 0.150 |
Why?
|
Osmosis | 3 | 2016 | 103 | 0.150 |
Why?
|
Diet Therapy | 1 | 2019 | 151 | 0.150 |
Why?
|
Administration, Oral | 5 | 2019 | 4015 | 0.150 |
Why?
|
Middle Aged | 27 | 2024 | 220858 | 0.150 |
Why?
|
Sleep Apnea Syndromes | 1 | 2006 | 977 | 0.140 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2019 | 297 | 0.140 |
Why?
|
Drug Approval | 1 | 2024 | 812 | 0.140 |
Why?
|
Cognition | 4 | 2020 | 6988 | 0.130 |
Why?
|
Dietary Supplements | 2 | 2020 | 3410 | 0.130 |
Why?
|
Clinical Trials as Topic | 3 | 2011 | 8002 | 0.130 |
Why?
|
Drug Tolerance | 1 | 2017 | 367 | 0.130 |
Why?
|
Mental Health | 1 | 2010 | 3251 | 0.130 |
Why?
|
Parietal Lobe | 2 | 2012 | 852 | 0.120 |
Why?
|
Psychotherapy | 1 | 2024 | 1646 | 0.120 |
Why?
|
Frontal Lobe | 2 | 2012 | 1416 | 0.110 |
Why?
|
United States | 4 | 2024 | 72341 | 0.110 |
Why?
|
Psychometrics | 1 | 2023 | 3061 | 0.110 |
Why?
|
Evidence-Based Practice | 1 | 2017 | 493 | 0.110 |
Why?
|
Severity of Illness Index | 9 | 2012 | 15841 | 0.100 |
Why?
|
Case-Control Studies | 7 | 2013 | 22174 | 0.100 |
Why?
|
Insurance, Health | 1 | 2024 | 2493 | 0.100 |
Why?
|
Psychiatry | 1 | 2024 | 1699 | 0.100 |
Why?
|
Drug Therapy, Combination | 2 | 2019 | 6304 | 0.090 |
Why?
|
Parents | 2 | 2023 | 3564 | 0.090 |
Why?
|
Terminology as Topic | 1 | 2017 | 1528 | 0.090 |
Why?
|
Emotional Intelligence | 1 | 2011 | 135 | 0.090 |
Why?
|
Autoantibodies | 1 | 2019 | 2119 | 0.090 |
Why?
|
Quality of Life | 3 | 2020 | 13367 | 0.080 |
Why?
|
Relaxation Therapy | 1 | 2010 | 181 | 0.080 |
Why?
|
Sampling Studies | 1 | 2010 | 615 | 0.080 |
Why?
|
Observation | 1 | 2010 | 310 | 0.080 |
Why?
|
Selection Bias | 1 | 2010 | 359 | 0.080 |
Why?
|
Dreams | 1 | 2009 | 146 | 0.080 |
Why?
|
Resilience, Psychological | 1 | 2016 | 788 | 0.070 |
Why?
|
Taiwan | 1 | 2009 | 522 | 0.070 |
Why?
|
Mental Disorders | 4 | 2013 | 6823 | 0.070 |
Why?
|
Age of Onset | 3 | 2009 | 3307 | 0.070 |
Why?
|
Status Epilepticus | 1 | 2012 | 461 | 0.070 |
Why?
|
Galantamine | 1 | 2006 | 33 | 0.070 |
Why?
|
Workplace | 1 | 2012 | 864 | 0.060 |
Why?
|
Depressive Disorder | 2 | 2016 | 3727 | 0.060 |
Why?
|
Employment | 1 | 2012 | 1114 | 0.060 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2007 | 306 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 10218 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20118 | 0.060 |
Why?
|
Cholinesterase Inhibitors | 1 | 2006 | 241 | 0.060 |
Why?
|
Exercise Test | 1 | 2012 | 2165 | 0.060 |
Why?
|
Heart Rate | 2 | 2012 | 4197 | 0.050 |
Why?
|
Activities of Daily Living | 1 | 2013 | 2420 | 0.050 |
Why?
|
Tic Disorders | 1 | 2024 | 136 | 0.050 |
Why?
|
Psychopharmacology | 1 | 2024 | 145 | 0.050 |
Why?
|
Psychology | 1 | 2024 | 356 | 0.050 |
Why?
|
Sleep Stages | 1 | 2006 | 695 | 0.050 |
Why?
|
Prospective Studies | 5 | 2019 | 54437 | 0.050 |
Why?
|
Attention | 1 | 2012 | 2394 | 0.050 |
Why?
|
Age Factors | 6 | 2010 | 18384 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2009 | 14610 | 0.050 |
Why?
|
Sex Distribution | 1 | 2006 | 2277 | 0.050 |
Why?
|
Self Report | 3 | 2020 | 3727 | 0.040 |
Why?
|
Nerve Net | 1 | 2012 | 2288 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12976 | 0.040 |
Why?
|
Residence Characteristics | 1 | 2010 | 2092 | 0.040 |
Why?
|
Accidents, Traffic | 1 | 2006 | 820 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2010 | 2317 | 0.040 |
Why?
|
Neurophysiology | 1 | 2020 | 144 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39127 | 0.040 |
Why?
|
Observer Variation | 1 | 2006 | 2610 | 0.040 |
Why?
|
Risk-Taking | 1 | 2005 | 1038 | 0.040 |
Why?
|
Antidepressive Agents | 1 | 2011 | 2893 | 0.040 |
Why?
|
Heart | 1 | 2012 | 4431 | 0.040 |
Why?
|
History, 21st Century | 1 | 2024 | 1567 | 0.040 |
Why?
|
Social Adjustment | 2 | 2011 | 632 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15308 | 0.030 |
Why?
|
History, 20th Century | 1 | 2024 | 2765 | 0.030 |
Why?
|
Sex Factors | 2 | 2006 | 10553 | 0.030 |
Why?
|
Prevalence | 2 | 2007 | 15721 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3584 | 0.020 |
Why?
|
Hypertension | 1 | 2012 | 8536 | 0.020 |
Why?
|
Placebos | 2 | 2006 | 1666 | 0.020 |
Why?
|
Drug Administration Schedule | 2 | 2010 | 4851 | 0.020 |
Why?
|
Prefrontal Cortex | 1 | 2020 | 2219 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2010 | 413 | 0.020 |
Why?
|
Risk Factors | 3 | 2011 | 74241 | 0.020 |
Why?
|
Cardiovascular Diseases | 2 | 2011 | 15521 | 0.020 |
Why?
|
Drug Substitution | 1 | 2010 | 291 | 0.020 |
Why?
|
Aggression | 1 | 2012 | 748 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3608 | 0.020 |
Why?
|
Wechsler Scales | 1 | 2007 | 257 | 0.020 |
Why?
|
Drug Interactions | 1 | 2011 | 1417 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2010 | 1577 | 0.020 |
Why?
|
Child Behavior | 1 | 2011 | 848 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2012 | 1393 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2012 | 1437 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2005 | 641 | 0.010 |
Why?
|
Drug Resistance | 1 | 2010 | 1594 | 0.010 |
Why?
|
Checklist | 1 | 2011 | 828 | 0.010 |
Why?
|
Research Design | 1 | 2020 | 6180 | 0.010 |
Why?
|
Patient Dropouts | 1 | 2006 | 411 | 0.010 |
Why?
|
Task Performance and Analysis | 1 | 2008 | 763 | 0.010 |
Why?
|
Time Factors | 2 | 2017 | 39957 | 0.010 |
Why?
|
Anxiety Disorders | 1 | 2012 | 2723 | 0.010 |
Why?
|
Family | 1 | 2011 | 3192 | 0.010 |
Why?
|
Demography | 1 | 2005 | 1641 | 0.010 |
Why?
|
Educational Status | 1 | 2007 | 2510 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2005 | 3418 | 0.010 |
Why?
|
Echocardiography | 1 | 2012 | 5006 | 0.010 |
Why?
|
Massachusetts | 1 | 2012 | 8837 | 0.010 |
Why?
|
Program Development | 1 | 2005 | 1294 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6224 | 0.010 |
Why?
|
Cardiovascular System | 1 | 2005 | 836 | 0.010 |
Why?
|
Aged | 3 | 2018 | 169292 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2012 | 14675 | 0.010 |
Why?
|
Blood Pressure | 1 | 2011 | 8479 | 0.010 |
Why?
|
Cognition Disorders | 1 | 2007 | 3976 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 36415 | 0.010 |
Why?
|
Concepts
(178)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(30)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_